keyboard_arrow_up

Abicipar Pegol Macular Edema and Degeneration Market Analysis & Forecast to 2023

RnRMarketResearch.com offers “Abicipar Pegol (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023” global research report on its store.

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Allergan’s abicipar pegol is a novel, long-acting anti-VEGF drug that is based on the DARPin technology. It is undergoing clinical development as a potential treatment for patients with wAMD, and a Phase III clinical trial is expected to begin in Q2 2015.

The Complete report is available at http://www.rnrmarketresearch.com/abicipar-pegol-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023-market-report.html .

Scope of The Report:

  • Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Abicipar Pegol including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Abicipar Pegol for the top country from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan

Reasons to Buy This Report:

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Abicipar Pegol performance.
  • Obtain sales forecast for Abicipar Pegol from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=312783 .

Table of Content for “Abicipar Pegol (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023” research report includes:

8 Abicipar pegol 77

8.1 Overview 77

8.2 Efficacy 79

8.3 Safety 80

8.4 Dosing and Formulation 81

8.5 Potential Clinical and Commercial Positioning 81

8.6 SWOT Analysis 82

8.7 Forecast 82

1.1 List of Tables

Table 1: ARM System Classification of AMD 21

Table 2: Symptoms of AMD 22

Table 3: National and International Treatment Guidelines for ME and AMD 35

Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013 36

Table 5: Leading Treatments for ME and AMD, 2014 51

Table 6: Unmet Needs and Opportunities in ME and AMD 53

Table 7: Promising Drugs in Clinical Development for ME and AMD 74

Table 8: Comparison of Drugs in Development for ME and AMD, 2014 75

Table 9: Product Profile - Abicipar pegol 79

Table 10: SWOT Analysis - Abicipar pegol, 2014 82

Table 11: Global Sales Forecast ($m) for Abicipar Pegol, 2013-2023 83

Table 12: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 105

Priced at US $3495 for a single user PDF, a discount on this research report can be requested at http://www.rnrmarketresearch.com/contacts/discount?rname=312783 .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. (http://www.rnrmarketresearch.com/latest_reports).